SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing significant downward pressure, with the community expressing deep frustration over the token's persistent decoupling from broader market gains and its continued decline to multi-year lows. While some investors remain anchored to the project's real-world utility and enterprise partnerships as a long-term thesis, many are actively debating whether the current price levels represent a historic buying opportunity or the final stages of a failed project.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is currently trending as investors weigh its attractive dividend yield and valuation against concerns over broadband subscriber erosion and long-term competition from satellite and fixed wireless providers. Community sentiment is divided, with many long-term holders highlighting the stock as a discounted income play bolstered by strong cash flow, while others remain skeptical due to the ongoing secular decline in traditional cable and lingering debt management questions.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing investor attention as holders actively debate its long-term potential compared to Bitcoin, with many monitoring upcoming network upgrades and technical breakout levels. Community sentiment remains polarized, featuring a mix of conviction-driven accumulation and vocal skepticism regarding the asset's performance relative to broader market movements.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened community engagement as investors track its critical role in connecting traditional banking infrastructure with blockchain through projects like the DTCC's tokenization services. Despite broader market frustration regarding token price performance, discussions remain anchored in the belief that Chainlink's indispensable oracle utility and upcoming regulatory clarity will eventually drive long-term value.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

401JK is garnering significant community attention driven by excitement surrounding a pending NFT collection drop and a long-standing mission to mock traditional finance systems. Supporters highlight the project's consistent development and 'Resist & Retire' narrative, while critics remain skeptical, questioning the asset's sustainability and long-term viability.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

The iShares Biotechnology ETF (IBB) is trending as investors monitor sector-wide rotation into high-beta small caps and aggressive M&A activity, with the community actively debating the durability of biotech's recent strength and its reliance on potential dovish policy shifts. Traders are closely tracking specific clinical catalysts and regulatory outcomes, particularly among oncology-focused names, as they weigh the potential for a sustained breakout against macroeconomic liquidity concerns.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is attracting significant investor attention as the community anticipates upcoming first-quarter earnings and updates on DefenCath's market penetration, particularly concerning potential partnerships with major dialysis providers. Investors are actively discussing the stock's recent price action, institutional ownership shifts, and the long-term impact of potential legislative support for kidney care payment reform.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is currently capturing significant community attention as a privacy-focused layer-one protocol leveraging COTIs Garbled Circuits for confidential smart contracts. While some investors are actively accumulating the token in anticipation of mainstream adoption and regulatory compliance, others are debating the project's long-term utility versus its connection to the Cardano ecosystem and its founder.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Papa John's International is currently in the spotlight following reports of a potential $65-per-share take-private deal involving TriArtisan Capital, a development that has triggered significant volatility and trading halts. While investors are actively debating the legitimacy of these reports and the company's long-term valuation, the community is closely monitoring for official confirmation as they weigh the stock's recent performance against the possibility of a buyout.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing intense investor focus as the market anticipates crucial Phase 3 data readouts for its MDD and GAD programs later this year. The community is actively debating the company's clinical prospects, capital runway, and competitive standing against rivals like Compass Pathways while speculating on the impact of potential regulatory breakthroughs and sector-wide volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why CRISPR Therapeutics Stock Has Been on a Roller-Coaster Ride This Year

Key PointsCommercial adoption remains slower than many investors expected...

CRISPR Therapeutics AG (CRSP) Ascends While Market Falls: Some Facts to Note

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $53.09, indicating a +2.06% shift from the previous trading day.

Moderna (MRNA) Surges 6.3%: Is This an Indication of Further Gains?

Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know  

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $50.27, denoting a +1.68% move from the preceding trading day.

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.47, signifying a -3.9% move from its prior day's close.

CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus?

CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus...

CRISPR Therapeutics Stock Is Absurdly Cheap -- Here's Why Analysts See 437% Upside Potential

Key PointsCRISPR's Casgevy cements the company as a leader in gene-editing therapies...

Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Out

Key PointsEli Lilly just posted encouraging results from a clinical trial for a gene-editing candidate...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Why Is CRSP Stock Falling Pre-Market Today?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.20	--	--	N/A
Q1 '26	-$1.22	-$1.28	-5.05%	MISSED
Q4 '25	-$1.16	-$1.37	-17.81%	MISSED
Q3 '25	-$1.26	-$1.17	7.15%	BEAT
Q2 '25	-$1.40	-$2.40	-71.24%	MISSED

CRSPCRISPR Therapeutics AG

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CRSP News